The Boao Lecheng Pilot Zone in Hainan stands out as China's sole special medical zone, fostering preferential policies tailored for the healthcare industries. This unique region has emerged as a pivotal gateway for international innovative pharmaceuticals and medical devices seeking fast-track entry into the Chinese market.

This streamlined process not only accelerates the entry of innovative healthcare solutions but also provides a significant competitive advantage, as multiple critical processes can be undertaken simultaneously.

The result is a dynamic ecosystem that enhances collaboration and expedites the introduction of cutting-edge medical advancements to Chinese Mainland.

Our partnering hospitals within the pilot zone conduct real-world clinical research on these products, allowing for concurrent preparation of application materials necessary for National Medical Products Administration (NMPA) approval.

The Greater Bay Area

GUANGDONG

127 million+ population

HONG KONG

7.4 million+ population

MACAO

713K+ population

The Guangdong-Hong Kong-Macao Greater Bay Area (GBA) stands out as a dynamic and economically robust region in China, showcasing remarkable growth and opportunities.

Several landmark initiatives have been rolled out in the Greater Bay Area (GBA) to enhance regional collaboration and healthcare accessibility.

Designated hospitals in the GBA can utilise Hong Kong-approved or Macao-approved drugs and medical devices, without prior NMPA certification . This development paves the way for more efficient medical practices and improved patient care.

Additionally, residents of Guangdong, Hong Kong, and Macao are now able to access undifferentiated social security services within the GBA, fostering a more integrated and supportive environment for all citizens.

These initiatives represent significant progress in harmonizing healthcare and social support systems across the region, ultimately benefiting the diverse population of the GBA.

Leveraging regional policy advantages for accelerated market entry

Together with its partners, Guorun strategically capitalises on regional policy advantages to expedite the market presence of international medical products in China.

The Bo'ao Lecheng International Medical Tourism Pilot Zone allows essential real-world clinical for accelerated NMPA approval and broader market penetration.

Simultaneously, the company targets the Guangdong-Hong Kong-Macao Greater Bay Area, where NMPA approval is not a prerequisite. This approach allows Guorun to quickly introduce its partners' innovative products to a significant segment of China’s population.

Through these dual strategies, Guorun positions itself at the forefront of the industry, facilitating access to advanced healthcare solutions while adhering to regulatory frameworks.